173 related articles for article (PubMed ID: 21481534)
1. Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.
Vajda A; Marignol L; Foley R; Lynch TH; Lawler M; Hollywood D
Cancer Treat Rev; 2011 Dec; 37(8):643-54. PubMed ID: 21481534
[TBL] [Abstract][Full Text] [Related]
2. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
Khatri A; Russell PJ
Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
[TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
Martiniello-Wilks R; Wang XY; Voeks DJ; Dane A; Shaw JM; Mortensen E; Both GW; Russell PJ
J Gene Med; 2004 Dec; 6(12):1343-57. PubMed ID: 15493036
[TBL] [Abstract][Full Text] [Related]
4. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.
Both GW
Curr Opin Mol Ther; 2009 Aug; 11(4):421-32. PubMed ID: 19649987
[TBL] [Abstract][Full Text] [Related]
6. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
[TBL] [Abstract][Full Text] [Related]
7. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
Greco O; Dachs GU
J Cell Physiol; 2001 Apr; 187(1):22-36. PubMed ID: 11241346
[TBL] [Abstract][Full Text] [Related]
8. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
Connors TA
Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for prostate cancer: where are we now?
Steiner MS; Gingrich JR
J Urol; 2000 Oct; 164(4):1121-36. PubMed ID: 10992352
[TBL] [Abstract][Full Text] [Related]
10. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
[TBL] [Abstract][Full Text] [Related]
11. Novel gene-directed enzyme prodrug therapies against prostate cancer.
Russell PJ; Khatri A
Expert Opin Investig Drugs; 2006 Aug; 15(8):947-61. PubMed ID: 16859396
[TBL] [Abstract][Full Text] [Related]
12. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.
Martiniello-Wilks R; Dane A; Voeks DJ; Jeyakumar G; Mortensen E; Shaw JM; Wang XY; Both GW; Russell PJ
J Gene Med; 2004 Jan; 6(1):43-54. PubMed ID: 14716676
[TBL] [Abstract][Full Text] [Related]
13. Strategies for enzyme/prodrug cancer therapy.
Xu G; McLeod HL
Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer gene therapy and the role of radiation.
Kaminski JM; Nguyen K; Buyyounouski M; Pollack A
Cancer Treat Rev; 2002 Feb; 28(1):49-64. PubMed ID: 12027414
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
[TBL] [Abstract][Full Text] [Related]
17. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
[TBL] [Abstract][Full Text] [Related]
18. Strategies for enhancing viral-based gene therapy using ionizing radiation.
Chmura SJ; Advani SJ; Kufe DW; Weichselbaum RR
Radiat Oncol Investig; 1999; 7(5):261-9. PubMed ID: 10580895
[TBL] [Abstract][Full Text] [Related]
19. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
[TBL] [Abstract][Full Text] [Related]
20. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]